AstraZeneca nabs 6 more months for Symbicort patent in latest court ruling
A federal judge in West Virginia ruled in favor of AstraZeneca on Wednesday, adding six months of patent protection for its asthma and COPD inhaler blockbuster Symbicort.
The latest ruling concerns a relatively new patent protection that AstraZeneca had obtained earlier this year. The new judgement on that case rules that Mylan (now Viatris) and Kindeva Drug Delivery infringed on five claims of that ‘588 patent.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.